Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Newmont Corporation — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $69.4 (market cap $30.93B), while Newmont Corporation trades at $113.1 (market cap $117.55B). The key difference: Newmont Corporation is far larger — about 3.8× GE HealthCare Technologies Inc. Common Stock's market cap, and Newmont Corporation pays the higher dividend (0.93%). Which is the better fit depends on your goals.
| GEHC | NEM | |
|---|---|---|
Market Cap | $30.93B | $117.55B |
Volume | 5,033,451 | 6,644,300 |
Sector | Health | Basic Materials |
52-Week High | $88.16 | $135.14 |
52-Week Low | $59.48 | $78.63 |
Enterprise Value | $39.39B | $114.14B |
Dividend Yield | 0.23% | 0.93% |
Typical Hold Time | — | 59 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Newmont Corporation (NEM) trades at $115.59, down 1.33% on the day, as the gold mining giant demonstrates strong fundamental performance with record revenue of $22.67 billion in 2025 and net income of $7.09 billion. The stock shows a bullish technical trend with support at $115 and resistance at $118, while maintaining attractive valuation metrics including a P/E of 14.58 and ROE of 25.53%. Recent news highlights the company's record $5.3 billion free cash flow and focus on per-share growth through operational improvements.
Newmont presents a compelling investment case with strong analyst support (76% buy ratings) and a $136.83 consensus price target representing 18% upside. The company's transformation from losses in 2022-2023 to robust profitability, coupled with disciplined capital allocation and gold price tailwinds, supports continued growth. Key risks include gold price volatility, operational execution challenges, and broader market conditions that could pressure mining stocks despite strong fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
